公开(公告)号：US10131873B2

公开(公告)日：2018-11-20

申请号：US14852311

申请日：2015-09-11

Applicant: Genentech, Inc.

Inventor： Natarajan Vijayasankaran ,  Steven J. Meier ,  Sharat Varma ,  Yi Yang

IPC: C12N5/02 ,  C12N5/18 ,  C12N5/00 ,  C07K16/00

Abstract: Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided.

公开(公告)号：US10017732B2

公开(公告)日：2018-07-10

申请号：US14211416

申请日：2014-03-14

Applicant: Genentech, Inc.

Inventor： Natarajan Vijayasankaran ,  Steven J. Meier ,  Sharat Varma ,  Yi Yang

IPC: A61K38/00 ,  C12N5/18 ,  C12N5/00 ,  C07K16/00

CPC classification number: C12N5/0018 ,  C07K16/00 ,  C07K2317/14 ,  C12N2500/30 ,  C12N2500/33 ,  C12N2500/44 ,  C12N2500/46

Abstract: Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided.

公开(公告)号：US09834753B2

公开(公告)日：2017-12-05

申请号：US14367813

申请日：2012-12-18

Applicant: Mogam Biotechnology Institute ,  Green Cross Labcell

Inventor： Bokyung Min ,  Hana Choi ,  Okjae Lim ,  Jung Hyun Her ,  Sangmi Kang ,  Eun-Kyoung Lee ,  Hyejin Chung ,  Yu Kyeong Hwang

IPC: C12N5/00 ,  C12N5/02 ,  C12N5/18 ,  C12N5/0783 ,  A61K35/17 ,  A61K38/38

CPC classification number: C12N5/0646 ,  A61K35/17 ,  A61K38/38 ,  C12N2501/2302 ,  C12N2501/515

Abstract: The present invention relates to a method for producing natural killer cells (hereinafter, referred to as “NK cells”), NK cells produced thereby, and a composition for treating cancers and infectious diseases containing the same. The present invention provides a method for producing NK cells, which maintain high cytotoxicity and cell viability to exhibit high therapeutic effects against cancers and infectious diseases and can be cultured ex vivo at high efficiency and high concentration. In addition, a culture method which maintains cell concentration at a constant level is used for the production of NK cells, and thus the overgrowth of the cells can be prevented so that the cells can be maintained at an optimal state. Particularly, even when the cells are thawed after freezing, the function of the cells is not impaired, and the NK cells can maintain high cell viability and cytotoxicity. Thus, the NK cells can be easily stored and supplied in a liquid or frozen state without needing an additional treatment process.

公开(公告)号：US09714410B2

公开(公告)日：2017-07-25

申请号：US11793784

申请日：2005-12-26

Applicant: Susumu Goto ,  Shohei Kishishita ,  Shinya Takuma ,  Chikashi Hirashima

Inventor： Susumu Goto ,  Shohei Kishishita ,  Shinya Takuma ,  Chikashi Hirashima

IPC: C12N5/00 ,  C12N5/18

CPC classification number: C12N5/0037 ,  C12N2500/80 ,  C12N2510/02

Abstract: It is an object of the present invention to allow a cell to produce a protein at a high level using a medium containing an enzymatic degradation product of fish meat or a fish meat extract. A method of culturing a cell comprising starting culturing in an initial medium and feeding at least once a feed medium to the initial medium during culturing, wherein at least one of the initial medium or the feed medium contains an enzymatic degradation product of fish meat or a fish meat extract added thereto. A method of producing a protein of interest using the above culture method.

公开(公告)号：US09714293B2

公开(公告)日：2017-07-25

申请号：US14670079

申请日：2015-03-26

Applicant: GENENTECH, INC.

Inventor： Martin Gawlitzek ,  Shun Luo ,  Christina Teresa Bevilacqua

IPC: C12N5/18 ,  C07K16/28 ,  C12N5/00 ,  C07K16/18 ,  C07K16/22 ,  C07K14/705

CPC classification number: C07K16/2878 ,  C07K14/70575 ,  C07K16/18 ,  C07K16/22 ,  C07K2317/14 ,  C07K2319/30 ,  C12N5/0018 ,  C12N5/0043 ,  C12N2500/32 ,  C12N2500/33 ,  C12N2500/90

Abstract: The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.

公开(公告)号：US09631216B2

公开(公告)日：2017-04-25

申请号：US14114639

申请日：2012-04-27

Applicant: Ruchika Srivastava ,  Sneha Lakshmandas Hemdev ,  Ankur Bhatnagar ,  Saravanan Desan ,  Anuj Goel ,  Harish Iyer

Inventor： Ruchika Srivastava ,  Sneha Lakshmandas Hemdev ,  Ankur Bhatnagar ,  Saravanan Desan ,  Anuj Goel ,  Harish Iyer

IPC: C12N5/10 ,  C12N5/00 ,  C12N5/18 ,  C12P21/00 ,  A61K39/395 ,  C07K16/00

CPC classification number: C12P21/00 ,  A61K39/39591 ,  C07K16/00 ,  C07K2317/14

Abstract: The present disclosure relates to a method of reducing heterogeneity in antibodies during culturing, wherein the heterogeneity is due to proportion of charge variant of the antibody. The disclosure also comprises a process of growing cells in a cell culture system that results in antibodies with the reduced heterogeneity. In one embodiment antibody heterogeneity is reduced by the addition of divalent transitional metal ions such as zinc (Zn2+) to the cell culture medium. In another embodiment antibody heterogeneity is reduced by decreasing the osmolality of the cell culture medium.

公开(公告)号：US09518250B2

公开(公告)日：2016-12-13

申请号：US14346160

申请日：2012-09-21

Applicant: CYTOMATRIX PTY LTD

Inventor： Melinda L. Tursky ,  Mark. A. Kirkland

IPC: A61K38/00 ,  C12N5/18 ,  C12N5/0789

CPC classification number: C12N5/0647 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/22 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2501/59 ,  C12N2501/998

Abstract: The present invention relates to hematopoietic cells, and more specifically to methods for long-term in vitro culturing and ex vivo expansion of hematopoietic cells. The present invention also provides compositions useful for culturing cells, such as media for culturing hematopoietic cells, specifically haematopoietic stem cells (HSC) and haematopoietic progenitor cells (HPC). The present invention further provides compositions including growth factor combinations and methods utilizing altered growth and environmental conditions that are applicable in vitro culturing and to ex vivo expansion of HSC and/or HPC.

Abstract translation: 本发明涉及造血细胞，更具体地涉及造血细胞的长期体外培养和离体扩增的方法。 本发明还提供了用于培养细胞的组合物，例如用于培养造血细胞的培养基，特别是造血干细胞（HSC）和造血祖细胞（HPC）。 本发明还提供包含生长因子组合的组合物和利用可用于HSC和/或HPC的体外培养和体外扩增的改变的生长和环境条件的方法。

公开(公告)号：US08980257B2

公开(公告)日：2015-03-17

申请号：US13698420

申请日：2011-05-17

Applicant: Makoto Kaneda ,  Yoshihiro Fujii ,  Yoshihiro Hayata ,  Yoshiro Kishi ,  Ichiro Yahara

Inventor： Makoto Kaneda ,  Yoshihiro Fujii ,  Yoshihiro Hayata ,  Yoshiro Kishi ,  Ichiro Yahara

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C07K16/18 ,  C07K16/24 ,  C12N15/00 ,  C12N15/09 ,  C12N15/11 ,  C12N15/13 ,  C12N15/63 ,  C12N5/10 ,  C12N5/16 ,  C12N5/18 ,  C12N5/20 ,  C12N5/22 ,  C12N5/24 ,  C12N5/26 ,  C12N5/28 ,  C07K16/22 ,  C07K14/495

CPC classification number: C07K16/22 ,  A61K2039/505 ,  C07K14/495 ,  C07K2317/24 ,  C07K2317/76

Abstract: It has been found out that among antibodies showing reactivity with wild type TGF-α, antibodies less reactive with G79A-substituted TGF-α have an excellent growth-suppressing effect on cancer cells having a mutated Ras gene. Further, it has been found out that most of these antibodies have an activity of inhibiting EGFR tyrosine phosphorylation and/or an induction-suppressing activity on vascular endothelial cells.

Abstract translation: 已经发现，在显示与野生型TGF-α的反应性的抗体中，与G79A取代的TGF-α反应性较差的抗体对具有突变的Ras基因的癌细胞具有优异的生长抑制作用。 此外，已经发现大多数这些抗体具有抑制EGFR酪氨酸磷酸化和/或对血管内皮细胞的诱导抑制活性的活性。

公开(公告)号：US20120302729A1

公开(公告)日：2012-11-29

申请号：US13514755

申请日：2010-12-09

Applicant: Renu Wadhwa ,  Sunil Kaul

Inventor： Renu Wadhwa ,  Sunil Kaul

IPC: C07K16/18 ,  C12N5/18 ,  A61P37/04 ,  C07K7/06 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/34 ,  C07K2317/76 ,  G01N33/57415 ,  G01N33/57423

Abstract: The present invention provides anti-mortalin peptide antibodies having stronger anticancer effects than known anti-mortalin antibodies, hybridomas producing such antibodies, and anticancer agents using such antibodies. Specifically, a hybridoma C-26 strain (FERM P-21875) and a hybridoma C-69 strain (FERM P-21876) producing anti-mortalin monoclonal antibodies having the function of being internalized by cancer cells and specificity to mortalin antigens, and having the good function of suppressing the cancer cell proliferation in vivo were obtained from hybridoma clones obtained using as an immunogen cocktail of the 2 types of peptide containing “LFGRAP” and “KAMQDAEVSKSDIGEVI” epitopes for an anti-mortalin antibody having the function of being internalized by cancer cells. Thus, anticancer agents containing the monoclonal antibodies as active ingredients could also be provided. Moreover, the epitope sequences recognized by these monoclonal antibodies were confirmed to be “EVILVG” and “DLFGR.”

Abstract translation: 本发明提供具有比已知抗赖群体抗体更强的抗癌作用的抗赖mort啉肽抗体，产生这种抗体的杂交瘤以及使用这种抗体的抗癌剂。 具体来说，产生具有被癌细胞内化的功能的抗赖群体单克隆抗体的杂交瘤C-26菌株（FERM P-21875）和杂交瘤C-69菌株（FERM P-21876），并且具有对mortalin抗原的特异性， 从使用含有LFGRAP和KAMQDAEVSKSDIGEVI表位的2种类型的肽作为免疫原液混合物获得的杂交瘤克隆获得抑制体内癌细胞增殖的良好功能，其具有由癌细胞内化的功能的抗赖群体抗体。 因此，也可以提供含有单克隆抗体作为活性成分的抗癌剂。 此外，由这些单克隆抗体识别的表位序列确认为EVILVG和DLFGR。

公开(公告)号：US20120294870A1

公开(公告)日：2012-11-22

申请号：US13549633

申请日：2012-07-16

Applicant: Vivian Takafuji ,  Xin Wei Wang ,  Edward J. Unsworth ,  Paul K. Goldsmith

Inventor： Vivian Takafuji ,  Xin Wei Wang ,  Edward J. Unsworth ,  Paul K. Goldsmith

IPC: C07K16/24 ,  A61K39/395 ,  C40B30/00 ,  G01N33/566 ,  C12Q1/68 ,  C12N5/18 ,  G01N33/577 ,  G01N21/76 ,  C12N15/13 ,  C12N15/63 ,  C12N1/21 ,  C12N1/19 ,  C12N5/10 ,  A61P35/00 ,  C12N5/09

CPC classification number: C07K16/2848 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/24 ,  C07K16/2884 ,  C07K16/40 ,  C07K2317/76 ,  G01N33/57438 ,  G01N33/57484 ,  G01N2333/52

Abstract: Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.

Abstract translation: 基于骨桥蛋白（OPN）和基质金属蛋白酶-9（MMP-9）在促进转移表型中的合作观察，公开了治疗和过度表达OPN的肿瘤如肝细胞癌（ HCC），例如转移性HCC。 在一个实例中，治疗肿瘤的方法包括施用减少由MMP-9切割产生的OPN片段（OPN-5kD）与CD44受体之间的相互作用而引起的细胞侵袭的药剂。 这些试剂的实例包括OPN-5kD片段和OPN-5kD特异性抗体。 还提供包括这些试剂的治疗组合物。 还提供了诊断或预后肿瘤的方法，例如通过检测从受试者获得的生物样品中OPN-5kD肽或OPN-cmRNA的表达。 还提供了特异性结合OPN-5kD的抗体。